New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab
Paolo Bortoluzzi, Silvia Mariel Ferrucci, Daniela Galimberti, F. Garavelli, Francesco Pozzo Giuffrida, Alessio Pizzati, Angelo Valerio Marzano, Chiara Mapelli
Abstract
Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre-existing ocular alterations belonging to the spectrum of AKC.
Topics & Concepts
DupilumabAtopic dermatitisSubclinical infectionMedicineDermatologyDiseaseInternal medicineDermatology and Skin DiseasesContact Dermatitis and AllergiesUrticaria and Related Conditions